98%
921
2 minutes
20
Background: This study evaluates the impact of Real-Time Prescription Benefits (RTPB), a tool integrated into electronic health records (EHRs), on patient out-of-pocket costs in an academic institution. RTPB provides prescribers with alternative, less expensive medications based on insurance plans. The primary measure was cost-savings, defined as the difference between the out-of-pocket cost of the prescribed medication and its alternative.
Methods: A retrospective analysis of prescriptions from outpatient clinics in a university-based health system was conducted between May 2020 and July 2021. Prescriptions were analyzed at the 2nd level of the Anatomical Therapeutic Chemical (ATC) classification system. Costs were standardized to a 30-day supply. Standardized cost and total cost per prescription, and overall savings for the top 20 medication classes at the 2nd ATC level were calculated. The overall impact of RTPB was estimated based on selecting the least expensive alternative suggested by RTPB.
Results: The study found that RTPB information was provided for 22% of prescriptions, with suggested alternatives for 1.26%. Among prescriptions with an alternative selected, the standardized average cost saving was $38.83. The study realized $15,416 in patient total cost savings. If the least expensive RTPB-suggested alternative were chosen for all prescriptions, an estimated $276,386 could have been saved. Psychoanaleptic and psycholeptic medications were the most prescribed with an alternative, with most savings in specialty drugs like anthelmintic and immunostimulant medications.
Conclusion: The study highlights the importance of RTPB in reducing patient costs. It reports patient cost-savings with RTPB in prescribing decisions. Future research could explore the impact of RTPB on medication adherence using pharmacy claims data.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227025 | PMC |
http://dx.doi.org/10.1016/j.rcsop.2024.100460 | DOI Listing |
J Prim Care Community Health
September 2025
Division of Nephrology, Department of Medicine, National University Hospital, Singapore.
Background: Chronic kidney disease (CKD) management was largely centered around renin-angiotensin-aldosterone system inhibitors (RAASi) optimization, until recent emergence of novel therapeutics. However, slow adoption of guideline-directed therapy leaves patients vulnerable to disease progression. In 2022, a data-driven informatics approach was introduced to track real-time adherence to best practices.
View Article and Find Full Text PDFRadiol Phys Technol
September 2025
Radiation and Proton Therapy Center, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-Cho, Shizuoka, 411-8777, Japan.
In therapy with Synchrony® mounted on Radixact®, the fiducial marker (FM) and adrenal gland metastasis, which shift with respiratory phase, require margin compensation for high-dose prescriptions. Although compensation is critical, no studies have examined the margin to compensate for the respiratory phase shift. Therefore, we aimed to suggest the compensating margin for the FM and adrenal metastasis shift along with respiratory phase.
View Article and Find Full Text PDFDrug Test Anal
September 2025
National Institute of Standards and Technology, Gaithersburg, Maryland, USA.
Over the last several years, there has been an influx of α-agonists into the street drug supply, beginning with the proliferation of xylazine, a potent veterinary sedative. Since 2023, another sedative, medetomidine, has been widely detected. Medetomidine, broadly, encompasses two enantiomers-dexmedetomidine and levomedetomidine-with the dex enantiomer being pharmacologically active and present in human-use pharmaceuticals.
View Article and Find Full Text PDFPharmacol Res
August 2025
Toxicology and Drug Metabolism Group, Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
During pregnancy there is an increased risk of vulvovaginal candidiasis that if left untreated is associated with pregnancy complications. First choice of treatment are over-the-counter azole antifungal drugs (AADs): miconazole, and clotrimazole, or prescription drug: fluconazole, which are suspected endocrine disruptive compounds. To investigate foetal exposure and endocrine disrupting effects of AADs on the human placenta, we added R-miconazole, S-miconazole, clotrimazole and fluconazole to the maternal reservoir of a dually recirculating ex vivo human term placental perfusion model.
View Article and Find Full Text PDFJ Manag Care Spec Pharm
September 2025
Division of General Internal Medicine, School of Medicine, University of Pittsburgh, PA.
Background: Chronic diseases such as diabetes are a major burden to the US health care system. High medication adherence helps improve diabetes outcomes and reduce cost. Cost of medications can contribute to nonadherence.
View Article and Find Full Text PDF